Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody

Tislelizumab is an anti-programmed death receptor 1 (PD-1) monoclonal immunoglobulin G 4 antibody developed by BeiGene. The structure of tislelizumab has been modified to maximally inhibit the binding of PD-1 to programmed death ligand 1 (PD-L1) and minimize the binding of tislelizumab to Fcγ recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lin, Geng, Zhihua, Hao, Bo, Geng, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Special Collection: Precise medicine in cancer control: from immunotherapy to artificial intelligence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358212/
https://www.ncbi.nlm.nih.gov/pubmed/35926155
http://dx.doi.org/10.1177/10732748221111296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358212/
https://www.ncbi.nlm.nih.gov/pubmed/35926155
http://dx.doi.org/10.1177/10732748221111296

Ejemplares similares